Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
Date:10/11/2007

immune system can attack the brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can progress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

According to the National Multiple Sclerosis Society, approximately 400,000 Americans acknowledge having MS, and every week about 200 people are diagnosed. Worldwide, multiple sclerosis may affect 2.5 million individuals.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indication in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppressio
'/>"/>

SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Bayer Wins Positive Response For Marketing Its Cancer Drug
4. Genomatix Licensed By Bayer Healthcare
5. Bayer to Market Biocon Insulin in China
6. Test for Esophageal Reflux Licensed to Bayer by University
7. Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
8. Dow Acquires Wolff Walsrode from Bayer
9. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
10. India to benefit from pharma companies move
11. South Africa Wins landmark case against pharmaceutical giants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 2015 , ... The FSH Society , the Massachusetts-based ... muscular dystrophy (FSHD), today announced the introduction of the first-ever care guideline for ... published today. , This new guideline condenses the results of nearly 60 ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Looking ... healthy smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental ... to take care of their teeth. , “Horizon is committed to offering our ...
(Date:7/27/2015)... AZ (PRWEB) , ... July 27, 2015 , ... The ... who are aging out of the foster care system to get into and complete ... Charitable Trust, was introduced at an event today with partners from across the ...
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a group ... Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of the ... by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program ... to support its mission of reducing the number of deaths and injuries occurring from ... and their families. PursuitSAFETY works with the police to find better and safer ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
... model that looks at different strategies for curbing ... isolation may be effective approaches when patients are ... superbugs, such as methicillin-resistant Staphylococcus aureas (MRSA), and ... infections, this type of modeling, if used to ...
... problem that needs to be addressed next is the epidemic ... together to discuss the latest in pain research and treatment ... Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in ... help of their physicians, have been asked to stop smoking ...
... otherwise healthy people have similar survival rates to younger ... older patients can undergo lung transplantation and have good ... patients from having the procedure, a new study says. ... Medical Center reviewed the records of 48 UCLA patients ...
... Proposed Changes in ... Lifesaving Effort, WASHINGTON, Feb. 16 As President Bush ... funded by the,President,s Emergency Plan for AIDS Relief (PEPFAR), the ... request, AIDS Healthcare,Foundation (AHF) ( http://www.aidshealth.org ) today cautioned the ...
... release is also available in French . ... flushing toxic chemicals into the ecosystem through municipal sewer ... comes from an unlikely source: estrogen. , After an ... amounts of estrogen present in municipal wastewater discharges can ...
... Crowder &,DeGaris, P.C. (http://www.cwcd.com ), has filed ... the United States, who allegedly suffered,permanent kidney damage ... to prevent excessive bleeding during coronary,artery bypass graft ... to CBS News, 60 Minutes will report Sunday ...
Cached Medicine News:Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 3Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: